Evaxion receives approval from fda to proceed with the clinical phase 2b study for evx-01

Copenhagen, denmark, jan. 03, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that the u.s. food and drug administration (“fda”) determined that the company may proceed with its phase 2b clinical trial of evx-01.

EVAX Ratings Summary

EVAX Quant Ranking